the introduction of cesium-131 represents the culmination of decades of work and millions of dollars of investment. top medical centers, hospitals and clinics across the united states are now offering this breakthrough treatment for cancer patients. the word brachytherapy derives from the greek prefix brachy, meaning “short” or “close,” because the titanium capsules containing the radioisotope are implanted directly into the cancerous prostate gland. treatment of cancer using low dose radiation or “seed” brachytherapy was pioneered in the 1960’s as an effective alternative to radical prostatectomy. pioneers in brachytherapy research initially theorized about the use of cesium-131 in a titanium capsule, however scientific and economic limitations at the time prevented its development and iodine-125 emerged as an alternative. beginning in 1967, iodine-125 became the first radioisotope manufactured in a titanium capsule, or seed. while its use continues to this day, many patients and doct
Company profile
Ticker
CATX
Exchange
Website
CEO
Lori Woods
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
Isoray, Inc., IsoRay, Inc., CENTURY PARK PICTURES CORP
SEC CIK
Corporate docs
Subsidiaries
Isoray Medical, Inc. • Isoray International, LLC • Viewpoint Molecular Targeting, Inc. • Perspective Therapeutics Pty Ltd ...
IRS number
411458152
CATX stock data
Latest filings (excl ownership)
DEFA14A
Additional proxy soliciting materials
18 Apr 24
DEF 14A
Definitive proxy
18 Apr 24
8-K
Completion of Acquisition or Disposition of Assets
16 Apr 24
EFFECT
Notice of effectiveness
10 Apr 24
424B3
Prospectus supplement
9 Apr 24
PRE 14A
Preliminary proxy
8 Apr 24
8-K
Changes in Registrant's Certifying Accountant
8 Apr 24
8-K
Entry into a Material Definitive Agreement
3 Apr 24
S-8
Registration of securities for employees
1 Apr 24
S-3
Shelf registration
29 Mar 24
Transcripts
CATX
Earnings call transcript
2023 Q1
10 Nov 22
CATX
Earnings call transcript
2023 Q1
10 Nov 22
CATX
Earnings call transcript
2022 Q4
29 Sep 22
CATX
Earnings call transcript
2022 Q4
28 Sep 22
CATX
Earnings call transcript
2022 Q3
11 May 22
CATX
Earnings call transcript
2022 Q3
10 May 22
CATX
Earnings call transcript
2022 Q2
9 Feb 22
CATX
Earnings call transcript
2022 Q2
8 Feb 22
CATX
Earnings call transcript
2022 Q1
11 Nov 21
CATX
Earnings call transcript
2022 Q1
10 Nov 21
Latest ownership filings
4
Change in insider ownership
8 Mar 24
SC 13D/A
Lantheus Holdings, Inc.
8 Mar 24
4
Robert F Williamson III
1 Feb 24
3
Initial statement of insider ownership
1 Feb 24
SC 13D
Lantheus Holdings, Inc.
1 Feb 24
4
Robert F Williamson III
30 Jan 24
4
Markus Puhlmann
26 Jan 24
4
Robert F Williamson III
26 Jan 24
4
Robert F Williamson III
26 Dec 23
4
Jonathan Robert Hunt
19 Dec 23
Financial summary
Quarter (USD) | Sep 23 | Jun 23 | Mar 23 | Sep 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Jun 22 | Jun 21 | Jun 20 | Jun 19 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 17.98 mm | 17.98 mm | 17.98 mm | 17.98 mm | 17.98 mm | 17.98 mm |
Cash burn (monthly) | 3.45 mm | 3.17 mm | 3.51 mm | 3.11 mm | 3.37 mm | 2.47 mm |
Cash used (since last report) | 22.97 mm | 21.16 mm | 23.41 mm | 20.75 mm | 22.47 mm | 16.48 mm |
Cash remaining | -4.99 mm | -3.18 mm | -5.43 mm | -2.77 mm | -4.49 mm | 1.50 mm |
Runway (months of cash) | -1.4 | -1.0 | -1.5 | -0.9 | -1.3 | 0.6 |
Institutional ownership, Q3 2023
6.2% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 49 |
Opened positions | 5 |
Closed positions | 5 |
Increased positions | 10 |
Reduced positions | 12 |
13F shares | Current |
---|---|
Total value | 9.11 bn |
Total shares | 36.50 mm |
Total puts | 0.00 |
Total calls | 0.00 |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|---|---|
Vanguard | 12.82 mm | $3.51 bn |
Baker Bros. Advisors | 7.64 mm | $2.09 bn |
BLK Blackrock | 4.54 mm | $1.24 bn |
Perkins Capital Management | 2.67 mm | $731.00 k |
Geode Capital Management | 2.52 mm | $689.01 mm |
Osterweis Capital Management | 1.58 mm | $433.02 mm |
HighTower Advisors | 1.15 mm | $314.00 mm |
STT State Street | 671.52 k | $183.80 mm |
Taylor & Morgan Wealth Management | 575.00 k | $157.38 mm |
NTRS Northern Trust | 393.31 k | $107.65 mm |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
6 Mar 24 | Lantheus Alpha Therapy | Common Stock | Buy | Acquire P | No | No | 0.95 | 60,431,039 | 57.41 mm | 116,773,394 |
30 Jan 24 | Robert F Williamson III | Common Stock | Buy | Acquire P | No | No | 0.7 | 3,500 | 2.45 k | 338,761 |
30 Jan 24 | Robert F Williamson III | Common Stock | Buy | Acquire P | No | No | 0.72 | 42,879 | 30.87 k | 335,261 |
30 Jan 24 | Robert F Williamson III | Common Stock | Buy | Acquire P | No | No | 0.71 | 57,121 | 40.56 k | 292,382 |
30 Jan 24 | Robert F Williamson III | Common Stock | Buy | Acquire P | No | No | 0.71 | 5,127 | 3.64 k | 235,261 |
30 Jan 24 | Robert F Williamson III | Common Stock | Buy | Acquire P | No | No | 0.71 | 18,579 | 13.19 k | 230,134 |
29 Jan 24 | Robert F Williamson III | Common Stock | Buy | Acquire P | No | No | 0.64 | 21,235 | 13.59 k | 211,555 |
29 Jan 24 | Robert F Williamson III | Common Stock | Buy | Acquire P | No | No | 0.64 | 4,031 | 2.58 k | 190,320 |
26 Jan 24 | Robert F Williamson III | Common Stock | Buy | Acquire P | No | No | 0.54 | 50,000 | 27.00 k | 186,289 |
26 Jan 24 | Robert F Williamson III | Common Stock | Buy | Acquire P | No | No | 0.55 | 25,000 | 13.75 k | 136,289 |
News
B. Riley Securities Maintains Buy on Perspective Therapeutics, Raises Price Target to $1.7
9 Apr 24
Stocks Pause As Traders Reassess Interest Rate Path, Gold Makes New Highs, Bitcoin Rebounds: What's Driving Markets Thursday?
28 Mar 24
Perspective Therapeutics FY2023 EPS $(0.14) Down From $(0.06) YoY, Sales $1.43M
28 Mar 24
Perspective Therapeutics Acquires CGMP-Compliant Manufacturing Facility; Financial Terms Not Disclosed
5 Mar 24
Perspective Therapeutics Announces $87.4M Private Placement Of 92,009,981 Shares Of Its Common Stock At A Price Of $0.95 Per Share
4 Mar 24
Press releases
Perspective Therapeutics to Participate at Upcoming April Investor Conferences
8 Apr 24
Perspective Therapeutics Provides Recent Business Highlights and Reports Fiscal Year 2023 Financial Results
28 Mar 24
Perspective Therapeutics Announces $87.4 Million Private Placement
4 Mar 24
Perspective Therapeutics Announces Closing of $69.0 Million Public Offering and $20.8 Million Private Placement
22 Jan 24